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The three-dimensional structure of Bcl-xL, an inhibitor
of apoptosis, suggests how different combinations of
proteins in the same family might be utilized to control
apoptosis.
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Programmed cell death (PCD) or apoptosis plays a funda-
mental role in the development and maintenance of cellu-
lar homeostasis. Homologous proteins and pathways in
apoptosis are found in many species, from worms to
humans; thus, regulating cellular demise appears to be a
critical activity in the life (and death) cycle of the cell in all
organisms. Although extracellular stimuli play a principal
role in switching on the cell-death response, the sensitivity
of a given cell to such stimuli is clearly cell-type specific
[1]. Checkpoints seem to exist along the pathway to cellu-
lar suicide, which are mediated by two different protein
families (Fig. 1) [2]. The primary checkpoint appears to
comprise the Bcl family of proteins, members of which can
act as repressors (A1, Bcl-2, Bcl-xL, Mcl-1) and effectors
(Bax, Bad, Bcl-xS) of apoptosis. The use of alternate com-
binations of Bcl family members appears to have the 
capability to either promote or block transmission of a cell-
death signal, although the intervening transducers of this
information have yet to be identified. The three-dimen-
sional (3D) structure of a death repressor from the Bcl
family, Bcl-xL, illustrates how different patterns of
oligomerization might act as a point of decision, a sort of
cellular ‘to be or not to be’ [3]. The secondary checkpoint
affects the foot soldiers of apoptosis itself namely, the
activity of the cysteine proteases (interleukin-converting
enzyme [ICE] and Ich [the analogous enzyme from
worms] proteases). These proteases presumably degrade
select proteins, ultimately destroying the means of their
own survival (Fig. 1). The extent of generalized proteolysis
is not presently known.
The Bcl family
Bcl-2, the founding member of the Bcl family, was origi-
nally identified at the t(14;18) breakpoint in follicular 
B-cell lymphoma [4]. The family is characterized by three
short regions of sequence similarity termed Bcl homology
(BH) domains 1, 2 and 3 (Fig. 2) [5]; each domain com-
prises only 15 to 20 amino acids of the »200 amino acids in
the full-length protein. The Bcl family comprises both
effectors and repressors of apoptosis; in addition, altered
splicing events are responsible for the dual role observed
for at least one member known as Bcl-x. The full length
Figure 1
Schematic pathway of cellular suicide. External stimuli initiate a program
of cellular suicide that is regulated at two checkpoints. The initial
intracellular death signal has yet to be identified and the number of
steps leading to Checkpoint 1 remains to be determined. The first
checkpoint represents the exchange of apoptotic repressors (e.g. Bcl-2)
with apoptotic effectors (e.g. Bax). Conversion of a Bax/Bcl-2
heterodimer to a Bax homodimer, for example, results in stimulation of
apoptosis and continuation to the next checkpoint in the PCD pathway.
Checkpoint 2 represents the interchange of subunits of ICE or Ich
proteases, which may result in a functional cysteine protease. Only a
properly constructed heterotetramer leads to an active enzyme. It is
presently unknown if there are any intervening regulatory checkpoints
between the Bcl and ICE/Ich protease checkpoints illustrated. (The
figure was adapted from [2], with permission.)
molecule, Bcl-xL (for long), represses apoptosis whereas a
truncated form of the protein lacking most of the BH2
domain, known as Bcl-xS (for short), acts as an apoptotic
effector [6].
The 3D structure of Bcl-xL [3], (in which the putative
transmembrane region at the C terminus is absent) reveals
a predominantly helical protein in which two centrally
located, primarily hydrophobic a helices (a5 and a6) are
surrounded by five amphipathic helices (Fig. 2). BH1 and
BH2 are constructed as helix-loop-helix modules in which
the loop forms an irregular structure. In conjunction with
the third conserved domain, BH3, the three homology
regions form an elongated hydrophobic cleft which may
form a surface for interaction with other Bcl family
members. Between a1 and a2 there is a highly disordered
loop of 52 amino acids (Ser28 to Val80). This segment fails
to display electron density in single crystals and no
medium or long-range NOEs are seen in NMR spectra in
solution that could be used to define its structure. For
deletion mutations in which some or all of this loop is
replaced by a tetrad of alanines, the anti-apoptotic activity
of Bcl-xL is not substantially altered upon interleukin-3
(IL-3) withdrawal (one means of inducing apoptosis in cell
culture). The biological role of this loop therefore remains
a mystery. It may be that it is induced to form a structural
interface when presented with an as yet unidentified com-
ponent of the PCD machinery, perhaps in response to
some death signals but not to others.
Genetic and molecular analyses of the BH domains indi-
cated that these conserved regions play an important role in
defining the biological consequence of bcl gene expression.
Selected mutations in either the BH1 or BH2 domains of
Bcl-2 disrupt the ability of Bcl-2 to heterodimerize with the
apoptotic effector Bax, thereby destroying the ability of
Bcl-2 to block apoptosis [7,8] (Fig. 3). But these mutants do
not block the ability of Bcl-2 to homodimerize, although no
biological significance has been attributed to homodimer-
ization, to date. Homodimerization occurs, possibly in a
head-to-tail orientation, via sequences in the N- and C-
termini [8,9]. It is interesting to note that some mutations
in Bcl-2 that disrupt heterodimerization with Bax and abro-
gate the ability of Bcl-2 to inhibit apoptosis do not have 
the same effect in Bcl-xL. For example, replacement of 
the segment Phe138–Arg–Asp–Gly141 in BH1 of Bcl-2
(131–134 of Bcl-xL) disrupts the interaction of Bcl-2 with
Bax with concomitant loss of cell viability upon IL-3 with-
drawal induced apoptosis [7]. But point mutants across this
identical segment in Bcl-xL, which block heterodimeriza-
tion with Bax, do not substantially diminish cell viability
after apoptotic induction with Sindbis virus [10]. Thus, the
functional significance of the BH domains seems to vary
among family members. The 3D structure of Bcl-xL pro-
vides the opportunity to conduct more detailed functional
mapping of the protein to define the true limits of these
domains and to identify whether they indeed form struc-
tural units within the protein. Once delimited, similar
efforts with different family members may lead to better
definitions of the characteristics of individual BH domains
that distinguish one protein from another.
Competing equilibria for different dimerizations among
Bcl family members has been proposed to form the basis
of a molecular rheostat for apoptotic regulation [2] (Fig. 4).
Formation of different partners can therefore be used to
stimulate or suppress cellular suicide, as in the first check-
point on the PCD pathway. Careful balancing of the ratios
of effector or repressor combinations has already been
shown to form the basis of this switch for a p53-initiated
death program [11]. There are hints that a similar process
occurs at the secondary checkpoint, in assembling the
active, heterotetrameric form of ICE proteases [12,13]. We
see evidence, therefore, that a scheme involving alterna-
tive patterns of protein oligomerization has the potential to
be a powerful regulatory mechanism. Indeed, this mecha-
nism was recognized long ago to be important in control-
ling gene expression. Two different transcription-factor
families contain a similar dimerization interface known as
a leucine zipper. The extent of transcriptional activation is
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Figure 2
Stereoview showing the arrangement of the
seven helices in the three-dimensional
structure of Bcl-xL. The three conserved
domains are BH1 (blue), BH2 (red) and BH3
(green). The large disordered loop is shown in
purple.
regulated, at least in part, by alternative pairing of protein
monomers that are capable of sequence-specific recogni-
tion of DNA as either homodimers or heterodimers [14].
The delivery of different DNA recognition surfaces is
mediated by the specificity of pairing determined at the
dimerization interface formed by the leucine zipper. In a
like manner, the BH1 and BH2 domains in the Bcl family
can permit formation of different combinations of proteins
that are capable of stimulating or repressing cellular
suicide (Fig. 4). What is needed is the identification of a
signalling surface that transmits the death signal beyond
the Bcl checkpoint. Is this simply a nonconserved domain
in a Bcl protein or is there another class of signalling mol-
ecule with which a Bcl oligomer must interact to stimulate
the assembly or activity of ICE or Ich proteases?
Points of influence
Although absent in the structural effort of Fesik and
coworkers [3], Bcl-xL and Bcl-2 possess a hydrophobic tail
capable of membrane insertion. Bcl-2 can be anchored to
mitochondrial and microsomal membranes via the
hydrophobic tail, with the balance of the protein facing
the cytosol [15,16]. Interestingly, there is a structural rela-
tionship between Bcl-xL and the pore-forming domain of
diphtheria toxin (Fig. 5). This domain of diphtheria toxin
is thought to dimerize and insert into the cell membrane,
thereby dissipating electrochemical gradients across a bio-
logical membrane [17]. Bcl-2 has recently been shown to
localize to the perinuclear membrane and to the endoplas-
mic reticulum (ER), in addition to its localization to mito-
chondria. Moreover, Bcl-2 directly or indirectly regulates
Ca2+ flux across the ER membrane [18]. The ability of
Bcl-2 to associate with different membranes and its struc-
tural relationship to diphtheria toxin (by analogy with the
structure of Bcl-xL) raises the intriguing possibility that
Bcl-2 may receive or even intercept cell-death signals
mediated by ion gradients [3].
Despite all of these attractive possibilities, the in vivo
roles of Bcl proteins have remained elusive. Bcl-2 has a
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Figure 3
The putative binding pocket of Bcl family
members. Molecular surface representations
of Bcl-xL are shown with the conserved
domains colored as in Figure 2. BH1 residues
in Bcl-2 whose mutation disrupts interaction
between Bcl-2 and Bax have been mapped
onto the molecular surface of Bcl-xL. (a)
These include residues Phe138–Gly141 and
Trp144–Arg146 of Bcl-2 (Phe131–Gly134
and Trp137–Arg139 of Bcl-xL), which have
been highlighted in yellow. (b) View shown
rotated approximately 90° about the vertical
axis relative to that in (a). The residues shown
here are Trp188, Gln190–Asp191 and
Glu200 of Bcl-2 (Trp181, Gln183–Asp184
and Glu193 of Bcl-xL), highlighted in yellow. It
is not known if it is only mutations in these
amino acids that can disrupt interaction
between Bcl-2 and Bax.
fairly wide tissue distribution in adults, including lym-
phoid, hematopoietic, epithelial and neural tissues [19,20].
But its expression is often limited to distinct cell types. In
epithelia, for example, bcl-2 is expressed within basal or
proliferating cells that are not terminally differentiated
[21]. Connections that are emerging between regulators of
cell life and cell death therefore suggest that mechanisms
of programmed cell death represent one more regulatory
checkpoint in the normal life cycle of the cell.
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